HELX invests in global companies benefitting from the advancements of genomic-based research techniques and technologies that are designed to extend or enhance the quality of life. The fund advisor uses fundamental research to identify and select stocks they feel best positioned to capitalize on such genomic advancements. Companies may include those that research, develop, produce or manufacture bionic devices, molecular medicine, pharmaceuticals and agricultural applications. HELX is one of the first three thematic funds to launch from Franklin Templeton.
公司网站 : https://www.franklintempleton.com/investor/investments-and-solutions/investment-options/etfs/overview/29097/franklin-genomic-advancements-etf
总经理:-
建立时间:2020
公司总部:Franklin Genomic Advancements ETF
领域:Miscellaneous
行业:Investment trusts/Mutual funds